The objectives of this symposium were to improve attendees’ knowledge on ADT, including the different therapeutic options ...

Local radiation therapy appears beneficial for men with bone metastatic hormone-sensitive prostate cancer (mHSPC).

Patients with metastatic prostate cancer may have improved survival outcomes after undergoing next-generation PSMA PET ...

Nonlinear association seen for effective castration period with metastasis-free survival for any ADT duration.

Bayer said on Monday that it has applied to the EU's drugs regulator for the use of Nubeqa, also known as darolutamide, in ...

The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. A supplemental new drug application has ...

In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...

A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy ...

Bayer announced the submission of an application to the European Medicines Agency for the oral androgen receptor inhibitor ...

Berlin: Bayer said on Monday that it has applied to the EU's drugs regulator for the use of Nubeqa, also known as ...

A new study sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy for prostate cancer, providing key insights for optimizing patient care.

ORION CORPORATION INVESTOR NEWS 14 OCTOBER 2024 at 11.00 EEST Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU Orion’s collaboration partner Bayer ...